Clinical trials: Fluorodeoxyglucose F18
Ovarian Cancer
Pilot Study to Evaluate 18F-fluorodeoxyglucose (FDG) Positron Emission Tomography /Computed Tomography (PET/CT) in Prediction of Early Response to Chemotherapy in Ovarian Cancer.
We hypothesize that 18FDG Positron Emission Tomography (FDG PET) imaging, carried out after the first cycle of chemotherapy, will identify responders, thus permitting early termination of potential toxic therapy in non…
- Trial name
- NCT00620243
- Testing
- 1: FDG PET
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Multiple Myeloma, Plasmacytoma
S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma
RATIONALE: Diagnostic procedures, such as magnetic resonance imaging (MRI) and fludeoxyglucose F 18 positron emission tomography (^18FDG-PET) may help diagnose solitary plasmacytoma.
- Trial name
- NCT00109889
- Testing
- magnetic resonance imaging, positron emission tomography
- Where
- 26 sites in United States
- Volunteers
- 2 people
- Sponsor
- SWOG Cancer Research Network
Acute Lung Injury, Early Pulmonary Neutrophilic Inflammation
PET Imaging in Patients at Risk for Acute Lung Injury
Despite decades of research, the mortality in acute lung injury remains very high and treatment options are very limited. Given these facts, the best treatment modality may be in prevention of this lethal syndrome.
- Trial name
- PET-ALI (NCT01486342)
- Testing
- PET-CT scan
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Washington University School of Medicine
Non Small Cell Lung Cancer, Circulating Tumor Cell
WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC
Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.
- Conditions
- Non Small Cell Lung Cancer, Circulating Tumor Cell, Circulating Tumor DNA
- Trial name
- WHENII (NCT03481101)
- Testing
- PET/CT
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Recurrent Melanoma, Stage IIIA Melanoma
FDG-PET in Advanced Melanoma
This clinical trial studies how well FDG-PET/CT measures early response in patients with stage III-IV melanoma who are receiving chemotherapy.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT02236546
- Testing
- [18F]fluorodeoxyglucose, Molecular assays on biopsied tissue, positron emission tomography
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Ischemic Heart Disease (IHD)
XTR003 PET Radiotracer for the Detection of Viable Myocardium
The study was designed to explore the clinical feasibility of XTR003, a PET myocardial fatty-acid tracer, for the detection of viable myocardium in patients with ischemic heart disease (IHD).
- Trial name
- NCT05885854
- Testing
- XTR003
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sinotau Pharmaceutical Group
Head and Neck Cancers, Lung and Esophagus Cancers
Adaptive Pet Study
The purpose of this study is to determine the benefit of using positron emission tomography (PET) in addition to the standard (computed tomography) CT to plan radiation therapy for cancer treatment.
- Conditions
- Head and Neck Cancers, Lung and Esophagus Cancers, Anal, Cervix, Vulvar, Vaginal, and Endometrium Cancers
- Trial name
- NCT01908504
- Testing
- PET-CT
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Duke University
Colo-rectal Cancer, Recurrence
F-18 FDG- PETCT in Staging and Recurrent Colorectal Cancer
Colorectal cancer (CRC) is the fourth most frequently diagnosed cancer and the second leading cause of cancer death in the United States.
- Trial name
- NCT03572595
- Testing
- F-18 FDG-PET/CT
- Volunteers
- 45 people
- Sponsor
- Assiut University
Venothromboembolism
Fluorodeoxyglucose (FDG)-Positron Emission Tomography (PET) in Cancer Associated Venothromboembolism
Venothromboembolic disease (VTE), which includes deep venous thrombosis (DVT) and pulmonary embolism (PE), is a severe health problem, effecting 1.5/1000 per year in the general population.
- Trial name
- NCT01107327
- Testing
- FDG-PET/CT
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Utah
Mild Cognitive Impairment
Biodistribution of [11C]Acetoacetate/[18F]Fluorodeoxyglucose in Subjects With Risk Factors for Alzheimer's Disease
This is a single center imaging study that will recruit 60 participants who are enrolled in the Effect of a Ketogenic Diet on Alzheimer's Disease Biomarkers and Symptoms: Brain Energy for Amyloid Transformation in AD (BEAT-AD)…
- Trial name
- AcAc PET (NCT03130036)
- Testing
- [11C]Acetoacetate[18F]Fluorodeoxyglucose positron emission tomography scan
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Esophageal Cancer, Lung Cancer
PET Scan in Patients With Lung and Esophageal Cancers That May Be Removed by Surgery
RATIONALE: Imaging procedures, such as fludeoxyglucose F 18 positron emission tomography (PET) scans, may improve the ability to detect lung and esophageal cancer or their recurrence.
- Trial name
- NCT00002930
- Testing
- positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Autoimmune Lymphoproliferative Syndrome, Lymphoma
Fluorodeoxyglucose Imaging Studies to Detect Lymphoma
Background: Autoimmune lymphoproliferative syndrome (ALPS) is a genetic disorder of the lymph system. People with ALPS often have swollen lymph nodes, especially in the neck and armpit.
- Trial name
- NCT01672918
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Schizophrenia, Healthy
Does Abnormal Insulin Action in the Brain Underlie Cognitive and Metabolic Dysfunction in Schizophrenia
Cognitive impairment (such as challenges in thinking and memory) is a core aspect of schizophrenia (SCZ), contributing to disability and poor functional outcomes.
- Trial name
- NCT05748990
- Testing
- Intranasal insulin
- Where
- Canada
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre for Addiction and Mental Health
Liver Cancer
Positron Emission Tomography Using Carbon-11 Acetate and Fludeoxyglucose F 18 in Detecting Hepatocellular Carcinoma (Liver Cancer) in Patients With Known or Suspected Liver Cancer
RATIONALE: Imaging procedures, such as carbon-11 acetate positron emission tomography (PET) and fludeoxyglucose F 18 PET, may improve the ability to detect hepatocellular carcinoma (liver cancer) and allow doctors to plan the…
- Trial name
- NCT00081094
- Testing
- 18F-Fluorodeoxyglucose-PET (FDG-PET), 11Carbon-Acetate-PET
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Washington University School of Medicine
Rectal Cancer
Use of Positron Emission Tomography/Computed Tomography (PET/CT) to Assess Tumor Response to Neoadjuvant Treatment for Distal Rectal Cancer
Preoperative chemoradiation therapy is the preferred initial treatment option for distal rectal cancers. However, assessing tumor response to preoperative chemoradiation therapy remains a challenge to the colorectal surgeon…
- Trial name
- NCT00254683
- Testing
- PET/CT with FDG
- Where
- Brazil
- Volunteers
- 100 people
- Sponsor
- University of Sao Paulo
Sarcoma, Multiple Myeloma
Study of F-Fluorodeoxyglucose (FluGlucoScan) in Patients With Known or Suspected Cancers of Low Incidence
Positron Emission Tomography (PET) is a specialised nuclear medicine procedure that uses positron emitting radiolabeled tracer molecules to measure biological activity.
- Conditions
- Sarcoma, Multiple Myeloma, Testicular Neoplasms, Ovarian Neoplasms
- Trial name
- NCT00123773
- Testing
- Positron Emission Tomography
- Where
- Canada
- Volunteers
- 1,075 people
- Sponsor
- AHS Cancer Control Alberta
Malignant Neoplasm of Breast, Hodgkin Disease
Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality
Identify the best combination of predictive variables that influence ionizing radiation dose and improved image quality through analysis and quantification of PET-CT images in simulators and patients.
- Conditions
- Malignant Neoplasm of Breast, Hodgkin Disease, Non-Hodgkin Lymphoma, Follicular (Nodular), Malignant Neoplasm of Bronchus and Lung
- Trial name
- pet-ct (NCT02378337)
- Testing
- Image quantify
- Where
- Brazil
- Volunteers
- 335 people, healthy volunteers welcome
- Sponsor
- Hospital Sao Rafael
Atherosclerosis, Type 2 Diabetes
High-sensitivity C-reactive Protein and United Kingdom Prospective Diabetes Study (UKPDS) Risk Score in Type 2 Diabetes
The UKPDS risk score is recommended to assess global risk for future coronary heart disease (CHD) events in primary prevention. Recently, high-sensitivity C-reactive protein (hsCRP) has emerged as a strong independent risk factor…
- Trial name
- NCT01099865
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Korea University
Pyrexia
Comparison of FDG-PET/CT and CECT-CAP as Upfront Imaging Modality for the Diagnosis of Pyrexia of Unknown Origin
Pyrexia of unknown origin (PUO) remains one of the most challenging diagnostic problems in modern medicine. Despite advances in laboratory diagnostics, microbiological techniques, imaging modalities, and molecular testing, a…
- Trial name
- CET-PET-PUO (NCT07816783)
- Testing
- FDG-PET, CECT, Standard care of therapy
- Where
- India
- Volunteers
- 132 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Ovarian Cancer, Primary Peritoneal Cancer
Positron Emission Tomography/Computed Tomography (PET/CT) in Relapsed Ovarian Cancer (MK-0000-143)
This study will characterize FDG-PET (18F-Fluorodeoxyglucose-Positron Emission Tomography) as an early response marker in recurrent, platinum-sensitive ovarian cancer treated with platinum-based therapy.
- Conditions
- Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT00959582
- Testing
- Comparator: 18-F-FDG PET/CT and Volumetric CT
- Volunteers
- 42 people
- Sponsor
- Merck Sharp & Dohme LLC